21:31 , Aug 19, 2019 |  BC Extra  |  Clinical News

Aug. 19 Clinical Quick Takes: Kalytera's cannabidiol shows promise for transplant, plus Abbisko and Brigham and Women's

Kalytera's CBD prevents graft-vs-host disease  Kalytera Therapeutics Inc. (TSX-V:KLY; OTCQB:KALTF) announced plans to start a Phase III registrational trial of cannabidiol after low and medium doses reduced the incidence of Grade 2-4 acute graft-versus-host disease...
20:37 , Aug 15, 2019 |  BioCentury  |  Finance

Deciphera’s $400M follow-on adds firepower on strength of GIST readout

Outsized investor demand continues unabated for stocks of companies with late stage clinical success stories, as evidenced by Deciphera’s ability to double the size of its follow-on to $400 million with little to no haircut...
23:33 , Aug 2, 2019 |  BC Extra  |  Company News

Aug. 2 Company Quick Takes: Daiichi's cancer drug gets U.S. approval, plus BioMarin, Acorda, Stemline and more

FDA approves Daiichi's pexidartinib  FDA approved Turalio pexidartinib from Daiichi Sankyo Co. Ltd. (Tokyo:4568) to treat tenosynovial giant cell tumor. A Daiichi spokesperson told BioCentury the drug has been launched at a wholesale acquisition cost...
00:02 , Jul 17, 2019 |  BC Extra  |  Company News

Abbisko builds combination strategy with China rights to X4's mavorixafor

Abbisko has licensed Greater China rights to X4’s mavorixafor, which the Shanghai-based company plans to use to develop a pipeline of combination therapies. The deal, for which financial terms are not disclosed, gives Abbisko Therapeutics...
21:58 , May 24, 2019 |  BioCentury  |  Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
23:26 , May 14, 2019 |  BC Extra  |  Clinical News

Daiichi gets ODAC split, with FDA panel backing pexidartinib for rare cancer

Missing data and lingering safety questions dogged a pair of Daiichi Sankyo oncology agents that came before ODAC on Tuesday, but a lack of available treatment options for tenosynovial giant cell tumor and a clear...
17:10 , Apr 23, 2019 |  BC Innovations  |  Distillery Therapeutics

SLC27A2 inhibition for lymphoma, lung, colorectal and cervical cancers

DISEASE CATEGORY: Cancer INDICATION: Lung cancer; T cell lymphoma; colorectal cancer; cervical cancer Mouse studies suggest inhibiting SLC27A2 could help treat T cell lymphoma and lung, colorectal and cervical cancers. In mouse models of T...
15:54 , Apr 17, 2019 |  BC Extra  |  Financial News

Turning Point gains after pricing upsized $166.5M IPO

Turning Point shares jumped $10.90 (61%) to $28.90 in their first day of trading Wednesday after the company raised $166.5 million in an upsized IPO priced late Tuesday. Turning Point Therapeutics Inc. (NASDAQ:TPTX) sold 9.3...
13:54 , Apr 15, 2019 |  BC Extra  |  Financial News

Chi-Med planning Hong Kong listing

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) announced its intent to list on the Hong Kong stock exchange via a global offering. The company has submitted an application seeking a listing in 3Q19; terms have yet...
18:59 , Apr 12, 2019 |  BC Week In Review  |  Company News

ODAC to discuss Daiichi Sankyo's pexidartinib, quizartinib NDAs

FDA’s Oncologic Drugs Advisory Committee will meet on May 14 to discuss two NDAs from Daiichi Sankyo, one for pexidartinib to treat symptomatic tenosynovial giant cell tumors and the other for quizartinib to treat relapsed...